A Study Comparing Tazarotene Cream 0.1% to TAZORAC® (Tazarotene) Cream 0.1% and Both to a Placebo Control in the Treatment of Acne Vulgaris

PHASE3CompletedINTERVENTIONAL
Enrollment

1,110

Participants

Timeline

Start Date

September 21, 2016

Primary Completion Date

May 31, 2017

Study Completion Date

May 31, 2017

Conditions
Acne Vulgaris
Interventions
DRUG

Tazarotene Cream 0.1%

Tazarotene Cream 0.1% applied to cover the affected areas of the face once daily for 84 +/- 4 days.

DRUG

Tazorac®

Tazorac® applied to cover the affected areas of the face once daily for 84 +/- 4 days.

DRUG

Placebo

Placebo (vehicle of the test product) applied to cover the affected areas of the face once daily for 84 +/- 4 days.

Trial Locations (25)

15241

Fougera Investigational Site, Upper Saint Clair

18201

Fougera Investigational Site, Hazleton

27262

Fougera Investigational Site, High Point

33015

Fougera Investigational Site, Miami

33027

Fougera Investigational Site, Miramar

33134

Fougera Investigational Site, Coral Gables

33169

Fougera Investigational Site, Miami Gardens

33172

Fougera Investigational Site, Sweetwater

33175

Fougera Investigational Site, Miami

37421

Fougera Investigational Site, Chattanooga

46168

Fougera Investigational Site, Plainfield

71913

Fougera Investigational Site, Hot Springs

72034

Fougera Investigational Site, Conway

78759

Fougera Investigational Site, Austin

85712

Fougera Investigational Site, Tucson

90010

Fougera Investigational Site, Los Angeles

90806

Fougera Investigational Site, Long Beach

90813

Fougera Investigational Site, Long Beach

91606

Fougera Investigational Site, North Hollywood

91786

Fougera Investigational Site, Upland

91790

Fougera Investigational Site, West Covina

91942

Fougera Investigational Site, La Mesa

92108

Fougera Investigational Site, San Diego

92801

Fougera Investigational Site, Anaheim

94582

Fougera Investigational Site, San Ramon

Sponsors
All Listed Sponsors
lead

Fougera Pharmaceuticals Inc.

INDUSTRY